vs

Side-by-side financial comparison of Emerson Electric (EMR) and Freeport-McMoRan (FCX). Click either name above to swap in a different company.

Freeport-McMoRan is the larger business by last-quarter revenue ($5.3B vs $4.3B, roughly 1.2× Emerson Electric). Emerson Electric runs the higher net margin — 13.9% vs 10.7%, a 3.2% gap on every dollar of revenue. On growth, Emerson Electric posted the faster year-over-year revenue change (4.1% vs -10.4%). Emerson Electric produced more free cash flow last quarter ($602.0M vs $-312.0M). Over the past eight quarters, Emerson Electric's revenue compounded faster (-0.3% CAGR vs -7.9%).

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

Freeport-McMoRan Inc., often called Freeport, is an American mining company based in the Freeport-McMoRan Center, in Phoenix, Arizona. The company is the world's largest producer of molybdenum, a major copper producer and operates the world's largest gold mine, the Grasberg mine in Papua, Indonesia.

EMR vs FCX — Head-to-Head

Bigger by revenue
FCX
FCX
1.2× larger
FCX
$5.3B
$4.3B
EMR
Growing faster (revenue YoY)
EMR
EMR
+14.5% gap
EMR
4.1%
-10.4%
FCX
Higher net margin
EMR
EMR
3.2% more per $
EMR
13.9%
10.7%
FCX
More free cash flow
EMR
EMR
$914.0M more FCF
EMR
$602.0M
$-312.0M
FCX
Faster 2-yr revenue CAGR
EMR
EMR
Annualised
EMR
-0.3%
-7.9%
FCX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EMR
EMR
FCX
FCX
Revenue
$4.3B
$5.3B
Net Profit
$605.0M
$565.0M
Gross Margin
53.2%
12.4%
Operating Margin
17.8%
15.4%
Net Margin
13.9%
10.7%
Revenue YoY
4.1%
-10.4%
Net Profit YoY
3.4%
-21.6%
EPS (diluted)
$1.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EMR
EMR
FCX
FCX
Q4 25
$4.3B
$5.3B
Q3 25
$4.9B
$6.8B
Q2 25
$4.6B
$7.5B
Q1 25
$4.4B
$5.6B
Q4 24
$4.2B
$5.9B
Q3 24
$4.6B
$6.7B
Q2 24
$4.4B
$6.4B
Q1 24
$4.4B
$6.2B
Net Profit
EMR
EMR
FCX
FCX
Q4 25
$605.0M
$565.0M
Q3 25
$637.0M
$1.2B
Q2 25
$586.0M
$1.5B
Q1 25
$485.0M
$793.0M
Q4 24
$585.0M
$721.0M
Q3 24
$996.0M
$1.2B
Q2 24
$329.0M
$1.3B
Q1 24
$501.0M
$1.2B
Gross Margin
EMR
EMR
FCX
FCX
Q4 25
53.2%
12.4%
Q3 25
51.9%
29.2%
Q2 25
52.6%
34.2%
Q1 25
53.5%
24.3%
Q4 24
53.5%
27.0%
Q3 24
51.3%
30.0%
Q2 24
52.8%
31.5%
Q1 24
52.2%
28.5%
Operating Margin
EMR
EMR
FCX
FCX
Q4 25
17.8%
15.4%
Q3 25
16.4%
28.9%
Q2 25
16.1%
32.3%
Q1 25
14.2%
23.4%
Q4 24
18.6%
21.1%
Q3 24
14.7%
29.0%
Q2 24
10.4%
32.0%
Q1 24
16.2%
26.3%
Net Margin
EMR
EMR
FCX
FCX
Q4 25
13.9%
10.7%
Q3 25
13.1%
18.3%
Q2 25
12.9%
20.6%
Q1 25
10.9%
14.2%
Q4 24
14.0%
12.3%
Q3 24
21.6%
18.5%
Q2 24
7.5%
20.0%
Q1 24
11.4%
18.7%
EPS (diluted)
EMR
EMR
FCX
FCX
Q4 25
$1.07
Q3 25
$1.12
$0.46
Q2 25
$1.04
$0.53
Q1 25
$0.86
$0.24
Q4 24
$1.02
Q3 24
$1.74
$0.36
Q2 24
$0.57
$0.42
Q1 24
$0.87
$0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EMR
EMR
FCX
FCX
Cash + ST InvestmentsLiquidity on hand
$3.8B
Total DebtLower is stronger
$7.6B
$9.4B
Stockholders' EquityBook value
$20.3B
$18.9B
Total Assets
$41.9B
$58.2B
Debt / EquityLower = less leverage
0.37×
0.50×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EMR
EMR
FCX
FCX
Q4 25
$3.8B
Q3 25
$4.3B
Q2 25
$4.5B
Q1 25
$4.4B
Q4 24
$3.9B
Q3 24
$5.0B
Q2 24
$5.3B
Q1 24
$5.2B
Total Debt
EMR
EMR
FCX
FCX
Q4 25
$7.6B
$9.4B
Q3 25
$8.9B
Q2 25
$8.3B
Q1 25
$8.2B
$9.4B
Q4 24
$6.6B
$8.9B
Q3 24
$7.7B
$9.7B
Q2 24
$7.1B
$9.4B
Q1 24
$7.6B
$9.4B
Stockholders' Equity
EMR
EMR
FCX
FCX
Q4 25
$20.3B
$18.9B
Q3 25
$20.3B
$18.7B
Q2 25
$19.9B
$18.2B
Q1 25
$19.2B
$17.7B
Q4 24
$20.5B
$17.6B
Q3 24
$21.6B
$17.5B
Q2 24
$20.8B
$17.4B
Q1 24
$20.9B
$17.0B
Total Assets
EMR
EMR
FCX
FCX
Q4 25
$41.9B
$58.2B
Q3 25
$42.0B
$56.8B
Q2 25
$42.5B
$56.5B
Q1 25
$42.0B
$56.0B
Q4 24
$42.6B
$54.8B
Q3 24
$44.2B
$55.4B
Q2 24
$45.6B
$54.6B
Q1 24
$46.4B
$54.2B
Debt / Equity
EMR
EMR
FCX
FCX
Q4 25
0.37×
0.50×
Q3 25
0.44×
Q2 25
0.42×
Q1 25
0.42×
0.53×
Q4 24
0.32×
0.51×
Q3 24
0.36×
0.55×
Q2 24
0.34×
0.54×
Q1 24
0.36×
0.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EMR
EMR
FCX
FCX
Operating Cash FlowLast quarter
$699.0M
$693.0M
Free Cash FlowOCF − Capex
$602.0M
$-312.0M
FCF MarginFCF / Revenue
13.9%
-5.9%
Capex IntensityCapex / Revenue
2.2%
19.1%
Cash ConversionOCF / Net Profit
1.16×
1.23×
TTM Free Cash FlowTrailing 4 quarters
$4.4B
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EMR
EMR
FCX
FCX
Q4 25
$699.0M
$693.0M
Q3 25
$3.1B
$1.7B
Q2 25
$1.1B
$2.2B
Q1 25
$241.0M
$1.1B
Q4 24
$777.0M
$1.4B
Q3 24
$3.3B
$1.9B
Q2 24
$1.1B
$2.0B
Q1 24
$743.0M
$1.9B
Free Cash Flow
EMR
EMR
FCX
FCX
Q4 25
$602.0M
$-312.0M
Q3 25
$2.7B
$608.0M
Q2 25
$977.0M
$934.0M
Q1 25
$154.0M
$-114.0M
Q4 24
$694.0M
$197.0M
Q3 24
$2.9B
$673.0M
Q2 24
$998.0M
$840.0M
Q1 24
$661.0M
$642.0M
FCF Margin
EMR
EMR
FCX
FCX
Q4 25
13.9%
-5.9%
Q3 25
54.9%
8.9%
Q2 25
21.5%
12.4%
Q1 25
3.5%
-2.0%
Q4 24
16.6%
3.4%
Q3 24
63.1%
10.1%
Q2 24
22.8%
13.1%
Q1 24
15.1%
10.3%
Capex Intensity
EMR
EMR
FCX
FCX
Q4 25
2.2%
19.1%
Q3 25
8.9%
15.5%
Q2 25
2.0%
16.8%
Q1 25
2.0%
21.0%
Q4 24
2.0%
21.1%
Q3 24
9.1%
17.9%
Q2 24
2.1%
17.4%
Q1 24
1.9%
20.2%
Cash Conversion
EMR
EMR
FCX
FCX
Q4 25
1.16×
1.23×
Q3 25
4.86×
1.33×
Q2 25
1.83×
1.42×
Q1 25
0.50×
1.33×
Q4 24
1.33×
1.99×
Q3 24
3.35×
1.51×
Q2 24
3.31×
1.53×
Q1 24
1.48×
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EMR
EMR

Other$1.8B41%
Software And Systems$1.0B24%
Intelligent Devices$996.0M23%
Safety And Productivity$503.0M12%

FCX
FCX

Morenci$2.5B47%
Grasberg Segment$964.0M18%
Copper In Concentrates$934.0M18%
Molybdenum$541.0M10%
Gold$388.0M7%

Related Comparisons